Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOAT1 | P35610 | 8/20 | 0.77 |
| ▸ | SOAT2 | O75908 | 6/20 | 0.77 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 6/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | XBP1 | P17861 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13678994 | 0.92 | SOAT1 (0.65) | SOAT1SOAT2ADORA1MAPTPOLB | |
| SCHEMBL1869316 | 0.89 | SOAT2 (0.61) | SOAT1SOAT2ADORA1MAPTPOLB | |
| SCHEMBL13772488 | 0.89 | SOAT2 (0.62) | SOAT1SOAT2ADORA1MAPTPOLB | |
| SCHEMBL16171342 | 0.87 | SOAT2 (1.00) | SOAT1SOAT2MAPTPOLBNPSR1 | |
| SCHEMBL19448012 | 0.87 | SOAT2 (1.00) | SOAT1SOAT2MAPTPOLBNPSR1 | |
| SCHEMBL16171341 | 0.87 | SOAT2 (1.00) | SOAT1SOAT2MAPTPOLBNPSR1 | |
| SCHEMBL13772482 | 0.85 | SOAT2 (0.57) | SOAT1SOAT2ADORA1MAPTPOLB | |
| SCHEMBL4148506 | 0.83 | MAPT (0.57) | SOAT1SOAT2MAPTPOLBRAB9A | |
| SCHEMBL4148523 | 0.83 | MAPT (0.57) | SOAT1SOAT2MAPTPOLBRAB9A | |
| SCHEMBL4139737 | 0.83 | MAPT (0.57) | SOAT1SOAT2MAPTPOLBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105597-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2011-05-05 | — | — | US | disclosed |
| US-20110105597-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2011-05-05 | — | — | US | disclosed |
| US-20110105597-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2011-05-05 | — | — | US | disclosed |
| US-20100280036-A1 | Modulation of Pathogenicity | QUONOVA, LLC | 2010-11-04 | — | — | US | disclosed |
| US-20100280036-A1 | Modulation of Pathogenicity | QUONOVA, LLC | 2010-11-04 | — | — | US | disclosed |
| US-20090076012-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2009-03-19 | — | — | US | disclosed |
| US-20090076012-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2009-03-19 | — | — | US | disclosed |
| US-20080214635-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2008-09-04 | — | — | US | disclosed |
| US-20080214635-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2008-09-04 | — | — | US | disclosed |
| US-20080194607-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2008-08-14 | — | — | US | disclosed |
| US-20080188536-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2008-08-07 | — | — | US | disclosed |
| US-20080188536-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2008-08-07 | — | — | US | disclosed |
| US-20080188535-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2008-08-07 | — | — | US | disclosed |
| US-20080188535-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2008-08-07 | — | — | US | disclosed |
| US-20080188491-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2008-08-07 | — | — | US | disclosed |
| US-20080182878-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2008-07-31 | — | — | US | disclosed |
| US-20080176938-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2008-07-24 | — | — | US | disclosed |
| US-20080176938-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2008-07-24 | — | — | US | disclosed |
| US-7335779-B2 | Modulation of pathogenicity | QUONOVA, LLC (US) | 2008-02-26 | — | — | US | disclosed |
| US-7335779-B2 | Modulation of pathogenicity | QUONOVA, LLC (US) | 2008-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076012-A1 | Modulation of pathogenicity | NR4A1, NR4A2, NR4A3 | SOAT1 561/4885SOAT2 693/4885ADORA1 834/4885 |
| US-20110105597-A1 | Modulation of pathogenicity | NR4A1, NR4A2, NR4A3 | SOAT1 566/4885SOAT2 715/4885ADORA1 859/4885 |
| US-20080214635-A1 | Modulation of pathogenicity | NR4A1, NR4A2, NR4A3 | SOAT1 566/4885SOAT2 715/4885ADORA1 859/4885 |
| US-20100280036-A1 | Modulation of Pathogenicity | NR4A1, NR4A2, NR4A3 | SOAT1 566/4885SOAT2 715/4885ADORA1 859/4885 |
| US-20080182878-A1 | Modulation of pathogenicity | NR4A1, NR4A2, MSR1 | SOAT1 560/4885SOAT2 714/4885ADORA1 870/4885 |
| US-20080188491-A1 | Modulation of pathogenicity | NR4A1, MSR1, NR4A2 | SOAT1 395/4885SOAT2 494/4885ADORA1 1165/4885 |
| US-20080194607-A1 | Modulation of pathogenicity | NR4A1, NR4A2, NR4A3 | SOAT1 566/4885SOAT2 715/4885ADORA1 859/4885 |
| US-20080188535-A1 | Modulation of pathogenicity | NR4A1, NR4A2, NR4A3 | SOAT1 566/4885SOAT2 715/4885ADORA1 859/4885 |
| US-20080188536-A1 | Modulation of pathogenicity | NR4A1, NR4A2, NR4A3 | SOAT1 566/4885SOAT2 715/4885ADORA1 859/4885 |
| US-20080176938-A1 | Modulation of pathogenicity | NR4A1, NR4A2, NR4A3 | SOAT1 470/4885SOAT2 711/4885ADORA1 731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.